CN110169571A - 用于提高生育能力的食疗组合物 - Google Patents
用于提高生育能力的食疗组合物 Download PDFInfo
- Publication number
- CN110169571A CN110169571A CN201910451903.4A CN201910451903A CN110169571A CN 110169571 A CN110169571 A CN 110169571A CN 201910451903 A CN201910451903 A CN 201910451903A CN 110169571 A CN110169571 A CN 110169571A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- group
- rat
- red
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 230000035558 fertility Effects 0.000 title claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 8
- 235000013305 food Nutrition 0.000 title claims abstract description 7
- 244000000626 Daucus carota Species 0.000 claims abstract description 7
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 240000006108 Allium ampeloprasum Species 0.000 claims abstract description 3
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims abstract description 3
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 3
- 240000007049 Juglans regia Species 0.000 claims abstract description 3
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 3
- 244000302512 Momordica charantia Species 0.000 claims abstract description 3
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 3
- 240000004760 Pimpinella anisum Species 0.000 claims abstract description 3
- 235000012550 Pimpinella anisum Nutrition 0.000 claims abstract description 3
- 235000021307 Triticum Nutrition 0.000 claims abstract description 3
- 244000098338 Triticum aestivum Species 0.000 claims abstract description 3
- 229960004999 lycopene Drugs 0.000 claims abstract description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 3
- 235000012661 lycopene Nutrition 0.000 claims abstract description 3
- 239000001751 lycopene Substances 0.000 claims abstract description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 3
- 210000000582 semen Anatomy 0.000 claims abstract description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 3
- 235000020234 walnut Nutrition 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 26
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 56
- 201000001431 Hyperuricemia Diseases 0.000 description 25
- 210000002381 plasma Anatomy 0.000 description 23
- 210000003734 kidney Anatomy 0.000 description 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 19
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 19
- 229940116269 uric acid Drugs 0.000 description 19
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 14
- 230000013011 mating Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 9
- 229960002529 benzbromarone Drugs 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- -1 Beta-N-acetylglucosamine glycosides Chemical class 0.000 description 7
- 206010020880 Hypertrophy Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108010093894 Xanthine oxidase Proteins 0.000 description 7
- 102100033220 Xanthine oxidase Human genes 0.000 description 7
- 239000002689 soil Substances 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000027326 copulation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 244000088415 Raphanus sativus Species 0.000 description 3
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 241000483399 Ipimorpha retusa Species 0.000 description 2
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 2
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000008627 kidney hypertrophy Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CPWPJLJWUXOOAB-UHFFFAOYSA-N benzene;bromine Chemical compound [Br].C1=CC=CC=C1 CPWPJLJWUXOOAB-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical group [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000387 litholytic effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/20—Malt products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种用于提高动物生育能力的食疗组合物,其技术要点是,由以下原料制备而成:小麦胚芽5~10重量份;苦瓜籽8~15重量份;韭菜籽10~15重量份;茴香籽6~8重量份;雌性红萝卜16~30重量份;黄瓜籽10~15重量份;枸杞子15~20重量份;黑芝麻12~20重量份;番茄红素5~8重量份;核桃仁8~10重量份。具有效果显著、无毒副作用、制备工艺简单、原料易得等优点。
Description
技术领域
本发明涉及一种含有天然植物的组合物,具体说是一种用于提高生育能力的食疗组合物。
背景技术
尿酸是人类嘌呤代谢的终产物,由次黄嘌呤、黄嘌呤在黄嘌呤氧化酶的作用下生成的,大部分出肾脏排除。在肝脏,黄嘌呤氧化酶可以催化次黄嘌呤氧化成黄嘌呤,进而黄嘌呤氧化成尿酸。在嘌呤代耐生成尿酸的过程中,黄嘌呤氧化酶起到主要的催化作用。黄嘌呤氧化酶之所以是人体内嘌呤代谢过程中非常重要的限速酶,是因为人体内不存在尿酸酶,不能使尿酸进一步分解为尿囊素。因此,抑制黄嘌呤氧化酶的活性在高尿酸血症的治疗中是重要的靶点。目前能抑制黄嘌呤氧化酶的药物主要是别嘌醇及新型选择型黄嘌呤氧化酶阻断药非布司他,但对于血尿酸水平较高及严重肾功能不全的患者使用非布司他疗效不佳,且因其经济成本较高和存在一定毒副作用而受到使用限制。
高尿酸血症是嘌呤代谢异常、尿酸排泄减少所致的血液中尿酸水平异常L高引起的代谢性疾病。随着人们生活水平的提高,饮食结构的改变,嘌呤饮食的增多,机体嘌呤的代谢发生紊乱,从而引起高尿酸血症的发生。大量的研究资料证实男性高尿酸血症人群存在性激素平衡紊乱的现象,患者本身性激素分泌紊乱加上生理、心理的影响导致患者(尤其是男性患者)性行为频率明显减少,严重影响其生活质量。
雌性红萝卜即“萝卜核-胞质雄性不育系”三系杂交萝卜,亦名莱菔,味辛、甘,性微温,入肺、胃二经,其种子、鲜根、叶均可入药。具有清热解毒、润肺止咳、化痰祛浊、生津止渴、滋阴补肾、疏肝理气,健胃消食等功效。雌性红萝卜具有超强促进肝、肾代谢功能的作用,它能快速启动肝肾自愈系统,具有超强的疏肝理气,入肺经,肺主皮毛,是补脾益气和补肾纳气用途的食品。
其内有丰富的“萝卜硫素”,其是一种多功能酶诱导物,可诱导机体产生Ⅱ型解毒酶一谷胱甘肽转移酶(GST)和醌还原酶(QR),此酶能中和可疑致癌物质,防止致癌物质破坏健康细胞内的遗传因子,从而起到抗癌作用,使癌细胞的恶性增殖得以控制,能有效地抑制包括结肠癌,胃癌,肺癌,前列腺癌,肝癌,结肠癌,黑色素瘤和神经母细胞瘤等移种人体肿瘤细胞生长。且具有抗癌作用强,毒副作用低,生物学性质稳定,可用于治疗和预防各种恶性肿瘤。
己有研究表明,多种药用植物成分,如某些黄酮类、萜类等为潜在的黄嘌呤氧化酶抑制剂,可开发为安全有效的抗痛风药物。郑俊波、金祖汉、张瑞君等在《“抗风红”降血尿酸作用研究》中通过酵母加腺嘌呤诱导高尿酸血症大鼠模型,阐明了雌性红萝卜降尿酸效果具有高度统计学意义。此外,其在人体上的利尿、溶石作用也已在具体临床实践中证明。而雌性红萝卜提高生殖能力的效果却鲜有报道。
发明内容
本发明的目的是提供一种用于提高生育能力的食疗组合物,从根本上解决了上述问题,其具有效果显著、无毒副作用、制备工艺简单、原料易得等优点。
为实现上述目的,本发明提供了如下技术方案:该用于提高生育能力的食疗组合物,其技术要点是,由以下原料制备而成:
小麦胚芽 5~10重量份
苦瓜籽 8~15重量份
韭菜籽 10~15重量份
茴香籽 6~8重量份
雌性红萝卜 16~30重量份
黄瓜籽 10~15重量份
枸杞子 15~20重量份
黑芝麻 12~20重量份
番茄红素 5~8重量份
核桃仁 8~10重量份。
进一步的,本发明还提供了上述组合物的制备方法,其技术要点是,包括以下步骤:
步骤1,将上述组合物的各原料分别制成冻干粉末;
步骤2,将步骤1制得的各组分的冻干粉末在真空环境下混合即得成品。
本发明的有益效果:
组合物各成分均采用天然植物直接制备而成,无需经过化学制剂提取或二次加工,制备工艺简单且无毒副作用,制备原材料易得。与现有治疗痛风的药物相比,对于服药与否的体质量影响变化相当。在长期服用时,其对于血浆尿酸含量、尿素氮含量、血浆肌酐含量及血浆β-N-乙酰氨基葡萄糖苷酶含量的改善效果明显优于现有化学药物。其对肾脏器官肥大性病变的抑制作用也明显优于同类药品。综上因素,可以说明本发明的组合物,在长期随饮食送服后,无副作用产生,能够溶解尿酸结晶(痛风石),并显著抑制尿酸结晶,改善身体机能的功能。
本发明的组合物不仅能改善痛风性关节炎而且能显著提高性欲。由于影响性行为的因素很多,机理也十分复杂。因此,要评判性能力,仅靠一个指标很难做出准确判断。因此,同时选择了交配潜伏期、交配次数、射精次数、射精潜伏期等观察指标。在雌雄鼠合笼过夜后,通过记录各组雌性大鼠孕产率及子代只数,进一步考察高尿酸血症雌性大鼠的生殖能力。交配能力实验结果表明,抗风红可显著增加高尿酸血症大鼠交配次数,缩短交配潜伏则,并可明显增强高尿酸血症大鼠交配能力,提高交配雌鼠的孕产率,说明抗风红具有良好的增强高尿酸血症大鼠生殖能力的作用。
附图说明
图1为本发明抗风红对高尿酸血症大鼠肾脏组织病理学改变的影响( HE 染色,200X)。
具体实施方式
以下通过具体实施例详细说明本发明的内容。
仪器与材料
1.1仪器
多功能酶标仪(美国ThermoScientific公司)
LeicaRM2235切片机(上海创迅医疗器械有限公司)
PHY-III病理组织漂烘仪(常州市中成电子仪器有限公司)
YD-60生物组织包埋机(金华市益迪医疗设备有限公司)
正置荧光显微镜(日本尼康公司)
1.2材料
实施例1~3各组分含量单位:kg
实施例3(以下称抗风红)
苯溴马隆片(昆山龙灯瑞迪制药有限公司)
非布司他片(江苏恒瑞医药股份有限公司)
氧嗪酸钾(大连美伦生物技术有限公司)
腺嘌呤(北京索莱宝科技有限公司)
酵母粉(北京奥博星生物科技有限公司)
尿酸测定试剂盒、肌酐测定试剂盒、尿素氮测定试剂盒、β-N-乙酰氨基葡萄糖苷酶试剂盒(南京建成生物工程研究所)
健康Wistar大鼠,清洁级,雄性,质量200±20g(辽宁长生生物技术股份有限公司)
2.方法
2.1药液配制
临用前将实施例3的各原料组分粉碎成粗颗粒,加适量生理盐水破壁机粉碎成浓度2g/ml的混悬液,根据需要稀释成高抗风红高剂量、低剂量、预防剂量组的药液。苯溴马隆、非布司他均临用前用生理盐水配制成10g/L备用。
大鼠高尿酸血症模型制备
除空白对照组外,其余各组均以氧嗪酸钾(100mg/kg)、腺嘌呤(200mg/kg)、酵母粉(10g/kg)联合灌胃4周,以制备高尿酸血症模型。其中抗风红预防剂量组上午给予等量上述造模剂以制备高尿酸血症模型,下午即灌胃给予抗风红(40g/kg);除预防剂量组外,其余各组给予等量生理盐水,连续4周。
分组与给药
106只健康雄性大鼠适应性喂养一周后,前70只大鼠随机分为7组,作为空白对照组,造模对照组,苯溴马隆组,非布司他组,抗风红高剂量、低剂量、预防剂量组,每组10只,用于评价抗风红对高尿酸血症大鼠治疗效果;后36只大鼠随机分为6组,即空白对照组,造模对照组,苯溴马隆组,非布司他组,抗风红高剂量、低剂量租,每组6只,用于评价抗风红对高尿酸血症大鼠生殖功能的影响。
造模成功后,苯溴马隆、非布司他组分别给予5mg/kg,抗风红高剂量、低剂量、预防剂量组分别以(40、20、40g/kg)灌胃给药。每天15:00给药一次,15ml/kg,空白对照组、造模对照组给予等量生理盐水,连续给药12周。
标本采集及指标检测
3.1一般状态观察
每天观察大鼠的饮食、饮水、体毛及精神状态,身体状态,排便排尿,垫料潮湿状况,并每周记录大鼠质量。
血浆生化指标测定
分别在给药l个月、两个月、三个月时,大鼠禁食不禁水12h眼球后静脉丛取血1.5ml后,静置0.5h后3000r/min离心10min分离血浆,分别使用试剂盒测定血浆中尿酸、肌酣、尿素氮及β-N-乙酰氨基葡萄糖苷酶含量。
交配能力观察
所有大鼠末次给药后,进行交配能力考察实验。将单只雄性大鼠放入笼中使其远应环境5min,然后放入l只非动情期雌鼠,致使雄性大鼠产生屡捕现象,记录下列指标:①自雌鼠投入,至雄鼠第一次扑捉雌鼠的时间(交配潜伏期);②自雌鼠投入,至雄鼠第l次射精的时间(射精潜伏期);③30min内雄鼠扑捉雌鼠的次数及射精次数;④30min内各组的扑捉百分率和射精百分率。雌雄鼠合笼过夜后,雌鼠单独饲养,记录其孕产率及子代个数。
大鼠肾脏肥大指数
以上指标考蔡元毕后,将各组大鼠麻醉后脱颈处死,解剖后冰上分离双肾、睾丸、附睾等,分别记录总重,计算肾脏肥大指数。器官肥大指数=(器官总重/体质量)×103。
组织病理学检测
将右肾于-80℃保存,左肾浸泡于4%多聚甲醛固定。组织固定后常规石蜡包埋,4μm连续切片,用苏木精-伊红染色,光镜下观察肾小管、肾小球以及肾脏病理改变和炎症细胞浸润情况。取右肾皮质匀浆后,按照试剂盒说明书测定各组大鼠肾皮质β-N-乙酰氨基葡萄糖苷酶。
统计学处理
实验数据采用统计软件SPSS21.0进行分析,计量资料以(x土s)表示。多样本均数的两两比较采用单因素方差分析,P<0.05为差异有显著意义;P<0.01表示差异具有非常显著意义。
结果
5.1对大鼠一般状态的影响
各组大鼠在造模前状态无区别。造模后,空白对照组饮水量、尿量无明显异常变化,反应机敏,活动正常,体毛有光泽,且无死亡情况;其他各组大鼠饮水量、尿量与正常组相比明显增加,且体毛干枯无光泽,活动减少,其中造模对照组在给药8周后有2只大鼠死亡、苯溴马隆组有l只太鼠死亡。
对大鼠体质量变化的影响
不同组别大鼠体质量变化结果如表l所示。结果表明,造模后,与空白对照组相比,造模对照、组体质量显著降低(P<0.05)。给药8周、12周后,与造模对照组比较,抗风红无论预防给药,还是治疗给药均能增加模型动物的体质量’(P<0.05或P<0.01),阳性药苯溴马隆、非布司他也能增加模型动物的体质量(P<0.05或P<0.01)。
表1抗风红对高尿酸血症模型大鼠体质量的影响(x土s,n≥8)
5.3对大鼠血浆尿酸、尿素氮介量的影响
不同组大鼠血浆尿酸、尿素氮含量变化结果如表2、表3所示。结果表明,造模对照组大鼠血浆尿酸、尿素氮含量一直维持在较高水平,与空白对照组相比差异均有非常显著意义(P<0.01),提示模型制备成功。灌胃给药4周后,除造模对照组外,其他各组大鼠血浆尿酸含量较造模对照组均有所降低,差异均有显著意义(P<0.05),且与抗风红高剂量、预防组相比差异具有非常显著意义(P<0.01)。给药8周、12周后,抗风红预防组血浆尿酸含盘明显降低,与造模对照组相比差异具有显著意义(P<0.05)。
给药4周、8周后,抗风红高、低剂量组,苯澳马降组血浆尿素氮水平较造模对照组显著降低,差异具有显著意义(P<0.05);非布司他组、抗风红预防组在给药4周、8周、12周后,其血浆尿素氮水平较造模对H黑组明显降低,差异均有非常显著意义(P<0.01)。
表2抗风红对高尿酸血症大鼠血浆尿酸含量的影响(x土s,n≥7)
表3 抗风红对高尿酸血症大鼠血浆尿素氮含量的影响(x土s,n≥8)
5.4对大鼠血浆肌酐、β-N-乙酰氨基葡萄糖苷酶含量的影响
不同组大鼠血浆肌由于含量变化结果如表4所示。除空白对照组外,各组大鼠血浆肌酐含量造模后均明显升高,与空白对照组相比差异均有非常思若意义(P<0.01)。给药4周后,苯溴马隆组和非布司他组较造模对照组肌酐含量明显降低,差异具有显著意义(P<0.05)。给药8周后,其他各组与造模对照组相比肌酐含量明显降低,差异具有显著意义(P<0.05)。
表4 抗风红对高尿酸血症大鼠血浆肌酐含量的影响(x土s,n≥8)
不同组大鼠血浆β-N-乙酰-D-葡萄糖苷酶含量变化结果如表5所示。结果表明,给药8周、12周后抗风红高剂量、预防剂量组,苯溴马隆组、非布司他组较造模对照组均能降低大鼠血浆β-N-乙酰-D-葡萄糖苷酶水平,差异具有显著意义(P<0.05),且抗风红组与苯溴马隆组、非布司他组作用相当。
表5 抗风红对高尿酸血症大鼠血浆β-N-乙酰氨基葡萄糖苷酶含量的影响(x土s,n≥8)
5.5大鼠肾脏组织变化
空白对照组大鼠肾脏外观无肿胀,色红有光泽,薄膜易于剥离,肾小球、肾小管形态正常,皮质、髓质分界清楚。造模及其他各组大鼠肾脏体积均有不同程度增大,两肾呈黄白色,表面旦颗粒状,肾包膜与肾实质黏连不易剥离,切面皮质髓质分界不清。其中造模对照组大鼠肾脏体积增大程度更为明显,双肾几乎为白色,而抗风红预防组大鼠肾脏外观与空白对照组相似。不同组大鼠肾器官肥大指数测定结果如表6所示,结果显示,与空白对照织相比,造模对照组大鼠肾器官肥大指数显著增加(P<0.05)。给药后各组大鼠肾器官肥大指数均降低,预防给药组降低的最为明显。与造模对照组比较,除苯溴马隆组外,其他各组大鼠肾器官肥大指数显著差异具有统计学意义(P<0.05或P<0.01)。
表6 抗风红对高尿酸血症大鼠肾脏榕官肥大指数的影响(x土s,n≥8)
5.6对高尿酸血症大鼠生殖行为能力的影响
抗风红高、低剂量组、苯溴马隆、非布司他组大鼠的平均交配潜伏期均低于造模对照组,平均交配次数、孕产率、平均子代数均高于造模对照组。其中抗风红高剂量组平均交配潜伏期、平均交配次数与造模对照组相比,差异具有最著意义(P<0.05),见表7。可见,抗风红高、低剂量均可增强高尿酸血症大鼠交配能力,抗风红高剂量组比低剂量组增加交配能力的作用更明显,其中子代雄/雌比例也明显提高。抗风红低剂量组增强交配能力的作用与阳性药苯溴马隆、非布司他相当,抗风红高剂量组均优于阳性药苯溴马隆、非布司他。
表7抗风红对高尿酸血症大鼠交配能力的影响(n=6)
5.结论
综合上述实验结果表明,抗风红能够显著降低大鼠血浆黄嘌呤氧化酶活性,提示抗风红可能是作为潜在的黄嘌呤氧化酶抑制剂从而发挥其降尿酸作用的。抗风红对大鼠实验性高尿酸血症具有预防和治疗作用,预防给药效果最好,非布司他次之。抗风红对腺嘌呤、氧嗪酸钾联合酵母膏造模时引起的大鼠肾损伤有明显的保护作用,预防给药效果最好。抗风红具有良好的增强高尿酸血症大鼠生殖能力的作用,其作用效果优于阳性药苯溴马隆、非布司他。
Claims (2)
1.一种用于提高动物生育能力的食疗组合物,其特征在于,由以下原料制备而成:
小麦胚芽 5~10重量份
苦瓜籽 8~15重量份
韭菜籽 10~15重量份
茴香籽 6~8重量份
雌性红萝卜 16~30重量份
黄瓜籽 10~15重量份
枸杞子 15~20重量份
黑芝麻 12~20重量份
番茄红素 5~8重量份
核桃仁 8~10重量份。
2.一种权利要求1所述组合物的制备方法,其特征在于,包括以下步骤:
步骤1,将上述组合物的各原料分别制成冻干粉末;
步骤2,将步骤1制得的各组分的冻干粉末在真空环境下混合即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910451903.4A CN110169571A (zh) | 2019-05-28 | 2019-05-28 | 用于提高生育能力的食疗组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910451903.4A CN110169571A (zh) | 2019-05-28 | 2019-05-28 | 用于提高生育能力的食疗组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110169571A true CN110169571A (zh) | 2019-08-27 |
Family
ID=67695795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910451903.4A Pending CN110169571A (zh) | 2019-05-28 | 2019-05-28 | 用于提高生育能力的食疗组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110169571A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101518336A (zh) * | 2009-04-14 | 2009-09-02 | 北京惠中铭捷生物科技有限公司 | 一种具有抗氧化功能的营养食品及其制备方法 |
CN102028021A (zh) * | 2009-09-28 | 2011-04-27 | 张瑞君 | 一种雌性萝卜(雄性不育萝卜)冻干粉 |
CN103251662A (zh) * | 2013-06-04 | 2013-08-21 | 张瑞君 | 雌性红萝卜冻干粉在制备治疗痛风药物中的应用以及其生产工艺 |
CN103933224A (zh) * | 2014-04-30 | 2014-07-23 | 周晓明 | 一种治疗痛风的中药组合物 |
CN104367749A (zh) * | 2014-10-16 | 2015-02-25 | 何万全 | 一种补益气血的药物组合物及其制备方法 |
CN107184831A (zh) * | 2017-03-27 | 2017-09-22 | 庄仰梅 | 一种治疗高脂血症的中药组合物及其制备方法 |
CN107821721A (zh) * | 2017-12-08 | 2018-03-23 | 沈阳萝膳堂医疗产业管理有限公司 | 一种具有治疗痛风的食疗组合物及其制备方法 |
US20190029987A1 (en) * | 2016-02-12 | 2019-01-31 | Universitat Zurich | Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum |
-
2019
- 2019-05-28 CN CN201910451903.4A patent/CN110169571A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101518336A (zh) * | 2009-04-14 | 2009-09-02 | 北京惠中铭捷生物科技有限公司 | 一种具有抗氧化功能的营养食品及其制备方法 |
CN102028021A (zh) * | 2009-09-28 | 2011-04-27 | 张瑞君 | 一种雌性萝卜(雄性不育萝卜)冻干粉 |
CN103251662A (zh) * | 2013-06-04 | 2013-08-21 | 张瑞君 | 雌性红萝卜冻干粉在制备治疗痛风药物中的应用以及其生产工艺 |
CN103933224A (zh) * | 2014-04-30 | 2014-07-23 | 周晓明 | 一种治疗痛风的中药组合物 |
CN104367749A (zh) * | 2014-10-16 | 2015-02-25 | 何万全 | 一种补益气血的药物组合物及其制备方法 |
US20190029987A1 (en) * | 2016-02-12 | 2019-01-31 | Universitat Zurich | Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum |
CN107184831A (zh) * | 2017-03-27 | 2017-09-22 | 庄仰梅 | 一种治疗高脂血症的中药组合物及其制备方法 |
CN107821721A (zh) * | 2017-12-08 | 2018-03-23 | 沈阳萝膳堂医疗产业管理有限公司 | 一种具有治疗痛风的食疗组合物及其制备方法 |
Non-Patent Citations (5)
Title |
---|
慈艳丽: "《百草纲目养生智慧全书》", 30 September 2016, 北京联合出版公司 * |
程小英等: "《绿色蔬菜的妙用》", 30 November 2001, 内蒙古科学技术出版社 * |
胡茂刚等: "《延年益寿八大黄金法则》", 31 March 2014, 金盾出版社 * |
邱灿亮等: "《中医调补保健康》", 30 June 2006, 上海科学技术文献出版社 * |
郑俊波等: ""抗风红"降血尿酸作用研究", 《求医问药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102670864A (zh) | 治疗心脑血管疾病和糖尿病的抗氧化功能的药物组合物 | |
Aja et al. | Evaluation of anti-diabetic effect and liver enzymes activity of ethanol extract of Pterocarpus santalinoides in alloxan induced diabetic albino rats | |
CN105943958A (zh) | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 | |
Ni et al. | Therapeutic effect of berberine on 60 patients with non-insulin dependent diabetes mellitus and experimental research | |
Hua et al. | Determination of SOD in black ginger extract and its effect on the liver of rats with type 2 diabetes | |
CN105920051A (zh) | 一种金针菇提取物及其制备方法与应用 | |
CN101147584B (zh) | 预防和治疗糖尿病的保健食品及其制备方法 | |
CN110169571A (zh) | 用于提高生育能力的食疗组合物 | |
CN101411781A (zh) | 普洱茶在制备治疗或预防糖尿病的药中的应用 | |
CN110170031A (zh) | 用于溶解痛风石的食疗组合物 | |
CN101829271B (zh) | 一种具有治疗糖尿病作用的中药复方及其制备方法和应用 | |
CN104548016A (zh) | 一种中药组合物在制备治疗高尿酸血症药物中的用途 | |
CN100408034C (zh) | 一种治疗白癜风、银屑病的中药制剂及其制备方法 | |
CN101829272B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN104305192A (zh) | 改善老年痴呆症患者记忆的功能性食品及其制备方法 | |
CN104415135A (zh) | 羟基多甲氧基黄酮类化合物及/或其衍生物的用途 | |
CN101804083B (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
CN108452240A (zh) | 一种抗肿瘤的中药组合物及其应用 | |
CN105726624A (zh) | 一种治疗糖尿病的药物组合物 | |
CN100455320C (zh) | 一种治疗地中海贫血的药物及其制备方法 | |
CN110507759A (zh) | 一种具有控制高血糖的三黄颗粒中药制剂及其制备方法 | |
CN110038090A (zh) | 一种具有抗痛风作用的复合芹菜籽油自乳化软胶囊及其制备方法 | |
AU2021105462A4 (en) | Use of fructus corni nano-powder in resisting type 2 diabetes mellitus | |
CN107496390A (zh) | 原苏木素a衍生物在保护化疗药物所致心脏损伤中的应用 | |
Katsuragi et al. | Transplantation of normal islets into the portal vein of Otsuka Long Evans Tokushima Fatty rats prevents diabetic progression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190827 |
|
RJ01 | Rejection of invention patent application after publication |